Systematic Review

Indian J Med Res 146, August 2017, pp 186-195
DOI: 10.4103/ijmr.IJMR_791_15

A review of Indian research on co-occurring cannabis use disorders & psychiatric disorders

Shalini Singh¹ & Yatan Pal Singh Balhara¹,²

¹Department of Psychiatry & ²National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, New Delhi, India

Received May 21, 2015

Background & objectives: Cannabis is a widely used illicit drug and its use is often associated with co-occurring psychiatric disorders. This systematic review was aimed to provide information on the published Indian studies on co-occurring cannabis use disorders and psychiatric disorders.

Methods: An electronic search of available Indian literature using relevant search terms was carried out in May 2015 and 52 articles in English language published from India were included in the current review.

Results: Studies on cannabis and associated psychotic disorders (n=16) chiefly described acute episodes with predominant positive symptoms, following cannabis use. Some studies (n=6) observed an overall increased prevalence of all psychiatric disorders and symptoms owing to cannabis use, while others (n=14) elaborated on high rates of substance use in those with psychiatric disorders. The effect of cannabis use on cognitive function was the focus of some of the Indian studies (n=7). All these studies barring one had all male subjects, and a single study described the service delivery model for those with dual diagnosis disorders in India. Most of the research used cross-sectional observational design and focussed on treatment-seeking population.

Interpretation & conclusions: A review of Indian literature on cannabis use and its association with psychiatric disorders indicates a high co-prevalence of psychotic disorders, especially in vulnerable individuals as well as high rates of co-occurrence of other psychiatric comorbidities. However, there is limited focus on exploring the aetiological association between cannabis use and psychiatric disorders; understanding the neurobiology of this association and management-related issues.

Key words Cannabis - comorbidity - dual diagnosis - dual disorders - psychosis - schizophrenia - substance use disorders

Cannabis is the most frequently used illicit psychoactive substance worldwide. In 2012, 125 to 227 million people were estimated to have used cannabis¹. The National Survey on Extent, Pattern and Trends of Drug Use in India also found it to be the most common illicit substance of use in the country².

Cannabis use has been associated with a high incidence of psychiatric disorders³,⁴. Cannabis use has been found to have a strong association with psychotic illness including schizophrenia⁵. This co-occurrence, which could also present as dual disorder or dual diagnosis, has important clinical implications as it
is often associated with diagnostic challenges, poor treatment outcome, severe illness course and high service utilization. Hence, it is important to study co-occurring cannabis use disorders and psychiatric disorders. The objective of the current review was to highlight salient features of the relevant Indian literature, to discuss the findings of these studies and to highlight the strengths and limitations of the existing work.

**Material & Methods**

**Search strategy:** Electronic databases of PubMed and IndMed were searched for relevant publications. The search was carried out in May 2015 and included publications till the month of May 2015. The PubMed, Boolean search was carried out using the combination of ‘diagnosis, dual (psychiatry)’ AND ‘India’. All publications listed using the search term ‘diagnosis, dual (psychiatry)’ were screened for Indian studies on co-occurring cannabis use disorders and psychiatric disorders. IndMed search was carried out using different search terms including ‘alcohol’, ‘cannabis’, ‘opiods’, ‘inhalants’, ‘sedatives’, ‘hallucinogens’, ‘stimulants’, ‘cocaine’, ‘amphetamine type stimulants’, ‘buprenorphine’, ‘pentazocine’, ‘dextropropoxyphene’, ‘heroin’, ‘opium’, ‘afeem’, ‘smack’, ‘morphine’, ‘bhang’, ‘charas’, ‘ganja’, ‘hashish’, ‘benzodiazepines’, ‘zolpidem’, ‘toluene’, ‘LSD’, ‘ketamine’, ‘caffeine’, ‘nicotine’ and ‘tobacco’. Electronic archives of Indian journals on psychiatry and psychology were also searched for relevant studies. Additional published material was identified from the bibliography of the studies screened and evaluated.

**Study selection:** Only English-language peer-reviewed studies from India conducted among human subjects were included. All published Indian researches on co-occurring substance use disorders and psychiatric disorders, irrespective of the type of substance and psychiatric disorder, were explored. The search was not restricted by the publication type, and various publication types such as original research articles, review articles, case reports, case series and trials (including randomized as well as open-label trials) were explored for the purpose of the current review. Studies that did not include cannabis use disorders were excluded. Further, experimental research not conducted at an Indian centre and animal studies were also excluded.

**Data extraction and analysis:** Information was extracted using a structured proforma from the studies that met the above-mentioned inclusion and exclusion criteria. Data were extracted pertaining to comorbid cannabis use disorders and psychiatric disorders. Two authors, using pre-defined criteria, extracted the information.

**Results**

Fifteen studies were found following search using Boolean search terms ‘diagnosis, dual (psychiatry)’ AND ‘India’, of which 10 were found relevant and included in the review. PubMed search with ‘diagnosis, dual (psychiatry)’ yielded 2957 studies, nine were relevant and included in the review. A search of IndMed archives led to 33 relevant studies. Twenty-eight studies on co-occurring cannabis use disorder and psychiatric disorders were included in the current review (Table I). Further, 24 studies on various psychoactive substances (including cannabis) and psychiatric disorders were included in the current review (Table II).

**Types of studies:** Thirty one studies included in the current review were cross-sectional observational studies. Other study types included reviews (nine publications), prospective observational studies (three publications), retrospective chart reviews (three publications), case-control study (one publication), letter to editor (one publication), case series (one publication), and editorial (one publication).

**Study population:** Most studies were conducted among male subjects and included treatment-seeking individuals. Two studies reported findings from general population. One study reported on family members and treatment centre staff.

**Psychoactive substances studied:** Cannabis was the exclusive psychoactive substance studied in 27 Indian studies on dual disorders. Twenty three studies reported findings on more than one psychoactive substances including cannabis.

**Psychiatric disorders studied:** Psychoses were studied in 27 publications. Other psychiatric disorders studied included bipolar affective disorder (BPAD) (three publications). Cognitive functions were explored in eight publications. More than one psychiatric disorder was explored in 14 publications.

**Time trends in publications on co-occurring cannabis use disorders and psychiatric disorders:** The first published journal article on co-occurring cannabis
### Table I. Studies that have explored co-occurring cannabis use disorders and psychiatric disorders in Indian setting (arranged in ascending order of year of publication)

| Study                        | Article type       | Study description                                                                 | Psychiatric disorder studied |
|------------------------------|--------------------|-----------------------------------------------------------------------------------|------------------------------|
| Dhunjiboy, 1930⁶             | Not available      | A detailed account of behavioural changes following cannabis use was provided     | Insanity                     |
| Grossman, 1969⁷              | Cross-sectional observational study | Behavioural symptoms following prolonged cannabis use (n=6)                       | Psychosis                    |
| Chopra, 1971⁸                | Cross-sectional observational study | Inpatients (n=200) with psychotic symptoms following cannabis use were assessed for personality features, type and duration of symptoms | Psychosis                    |
| Varma, 1972⁹                 | Cross-sectional observational study | Description of socio-demographic and illness variables of inpatients (n=1248) with cannabis psychosis. Elaboration of personality features and psychotic syndromes in cannabis users | Psychosis                    |
| Thacore, 1973¹⁰              | Not available      | Described cannabis intoxication                                                    | Psychiatry                   |
| Chopra and Smith, 1974¹¹     | Cross-sectional observational study | Socio-demographic variables, substance use characteristics and psychotic illness variables of patients (n=200) were observed following intoxication | Psychiatry                   |
| Agarwal et al, 1975¹²        | Cross-sectional observational study | Detailed physical and psychological evaluation of long-term (>5 years) consumers of 'bhang' revealed no physical abnormality and cognitive defects in some (20%) | Cognitive functions |
| Dube et al, 1975¹³           | Cross-sectional observational study | Looked for rates of cannabis use (24%) in psychiatric inpatients (n=566) and found a high association between cannabis use and 'toxic psychosis' (96%) | Various disorders |
| Goel and Netto, 1975¹⁴       | Retrospective study | Evaluation of clinical features, prevalence (14.4%) and pattern of cannabis use in psychiatric inpatients (n=334) with detailed description of regular users with induced psychosis | Psychiatry                   |
| Thacore and Shukla, 1976¹⁵   | Cross-sectional observational study | Comparison of behavioural manifestations of patients with cannabis psychosis (25) and those with paranoid schizophrenia (n=25) | Psychiatry                   |
| Bagadia et al, 1976¹⁶        | Cross-sectional observational study | Detailed evaluation of regular cannabis users (n=20) who were psychiatric inpatients. Nine of them developed schizophrenia | Various disorders |
| Wig and Verma, 1977¹⁷        | Cross-sectional observational study | Cannabis users (n=23) were matched with non-users (n=11) to look for differences on physical and psychological evaluation. Cognitive changes were discernible | Cognitive functions |
| Chopra and Smith, 1974¹¹     | Cross-sectional observational study | Patients presenting with acute psychotic episodes (n=200) were assessed for cannabis use and related behavioural changes | Psychiatry                   |
| Menhiratta et al, 1978¹⁸     | Cross-sectional observational study | Long-term cannabis users (n=50) underwent psychological and cognitive testing and results were compared against matched controls (n=25) and cognitive deficit was found | Psychiatry                   |
| Ray et al, 1978¹⁹            | Cross-sectional observational study | Long-term use of cannabis and its cognitive effects (n=30) were measured and compared with matched controls (n=50) | Cognitive functions |

Contd...
use disorder and psychiatric disorders dated back to the 1930s. During the four decades from the 1960s to 1990s, the largest proportion of publications on dual disorders focussed exclusively on cannabis. However, the contribution of publication that focussed on cannabis use reduced during the 2000s and 2010s (Figure).

**Cannabis use disorders and psychotic disorders:** Sixteen studies described comorbid cannabis use disorders and psychiatric disorders dated back to the 1930s. During the four decades from the 1960s to 1990s, the largest proportion of publications on dual disorders focussed exclusively on cannabis. However, the contribution of publication that focussed on cannabis use reduced during the 2000s and 2010s (Figure).

| Study                      | Article type | Study description                                                                 | Psychiatric disorder studied          |
|----------------------------|--------------|-----------------------------------------------------------------------------------|---------------------------------------|
| Sethi et al, 1981<sup>20</sup> | Cross-sectional observational study | Chronic cannabis users (n=50) were evaluated for social, economic, physical and cognitive decline | Cognitive functions                   |
| Mendhiratta et al, 1988<sup>21</sup> | Cross-sectional observational study | Follow up after 9-10 yr of previous study<sup>10</sup> cases (n=30) and controls (n=15) to look for cognitive deficits after long-term use | Cognitive functions                   |
| Varma et al, 1988<sup>22</sup> | Prospective observational study | Heavy chronic cannabis users (n=26) were evaluated for social, occupational and cognitive dysfunction | Cognitive functions                   |
| Thomas, 1993<sup>23</sup> | Review | Discussed evidence on phenomenology of cannabis intoxication and reaction to cannabis use to create basis for cannabis use psychosis | Psychosis                             |
| Basu et al, 1994<sup>24</sup> | Review | Discussion of literature on specific phenomenology of cannabis use related psychiatric disorders | Various disorders                     |
| Basu et al, 1999<sup>25</sup> | Case-control study | Retrospective chart review to compare between cases of cannabis psychosis (n=20) and acute psychosis (n=20) on socio-demographic, illness and substance use variables | Psychosis                             |
| Sarkar et al, 2003<sup>26</sup> | Retrospective study | Psychiatric disorders, socio-demographic characteristics, substance use patterns of cannabis users (244) were recorded using retrospective chart review | Various disorders                     |
| Grover and Basu, 2004<sup>27</sup> | Review article | Review of the past 15 yr evidence on cannabis use and associated psychopathology | Various disorders, withdrawal syndrome and cognitive deficit |
| Chaudhury et al, 2005<sup>28</sup> | Cross-sectional observational study | Nature of psychiatric symptoms and socio-demographic variables of cannabis using psychiatric inpatients (n=67) have been described | Various disorders                     |
| Kulhalli et al, 2007<sup>29</sup> | Cross-sectional observational study | Treatment-seeking patients (n=20) specifically with psychosis following cannabis use were evaluated for psychopathology | Psychosis                             |
| Parakh and Basu, 2013<sup>30</sup> | Review article | Review of recent literature to assess strength of association between cannabis and psychosis with a special emphasis on genetic studies | Psychosis                             |
| Shrivastava et al, 2014<sup>31</sup> | Review article | Review of Indian literature on psychiatric comorbidity in substance use disorders | Psychosis                             |
| Ghosh and Basu, 2015<sup>32</sup> | Review article | Review of evidence on cannabis use and associated psychopathology (2003-2013) | Various disorders, withdrawal syndrome and cognitive deficit |

Socio-demographic attributes 1248 inpatients receiving treatment for psychotic disorder associated with long-term use of cannabis. Thacore<sup>10</sup> described four long-term *bhang* users who developed schizophrenia-like psychosis associated with thought and perceptual disturbances in the absence of a state of confusion. Chopra and Smith<sup>11</sup> described the clinical and demographic findings of 200 Indian patients who presented with symptoms, suggestive of psychosis due to use of cannabis. Five per cent individuals were found to have presented with a pre-existing psychiatric illness, while 58 per cent were found to have covert
| Study                        | Article type   | Study description                                                                                                                                                                                                                                                                                                                                 | Psychiatric disorder studied |
|-----------------------------|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|
| Dubé and Handa, 1971<sup>33</sup> | Cross-sectional observational study | General population survey (n=16,725) to ascertain the prevalence of mental disorders and correlate with ‘drug use habits’ suggesting significantly high prevalence of mental disorders among users | Various disorders              |
| Trivedi and Sethi, 1978<sup>34</sup> | Cross-sectional observational study | Psychiatric outpatients (n=1000) were screened for drug abuse prevalence (16.4%) and prevalence of substance use in each disorder was measured                                                                                                                                             | Various disorders              |
| Thomas et al, 1979<sup>35</sup> | Cross-sectional observational study | Drug use patterns and prevalence among adolescents (n=439) were determined and correlated with findings on personality tests                                                                                                                                                                                                                     | Personality                   |
| Kisore et al, 1994<sup>36</sup>  | Cross-sectional observational study | Psychiatric comorbidity was measured in alcohol and opioid dependent individuals (n=43). High rates of mood disorders (20.9%) and other substance use disorders (16.3%) were observed                                                                                                    | Various disorders              |
| Bannerjee et al, 1997<sup>37</sup> | Cross-sectional study | Substance dependent individuals (n=96) were assessed on various tests to assess cognitive defect and emotional imbalance following drug use                                                                                                                                                                                                 | Cognitive functions           |
| Kumar and Raju, 1998<sup>38</sup> | Prospective observational study | Manic patients (n=100) were screened for substance use and high rates of use were recorded (52%). Course of illness was observed for next three months and compared with that of non-users                                                                                                     | Mania                         |
| Basu and Gupta, 2000<sup>39</sup> | Review article | Authors have thrown light on aspects of dual diagnosis such as prevalence rates and management issues                                                                                                                                                                                                                                           | Not applicable                |
| Carey et al, 2003<sup>40</sup>  | Cross-sectional observational study | AUDIT and DAST instruments were administered on inpatients (n=1349) with psychiatric and substance use disorders to assess psychometric properties                                                                                                                                                                                      | Various disorders              |
| Goswami et al, 2003<sup>41</sup> | Cross-sectional observational study | Course of concurrent substance use disorders and schizophrenia in outpatients (n=22) were compared to look for association                                                                                                                                                                                                                      | Schizophrenia                 |
| Aich et al, 2004<sup>42</sup>  | Cross-sectional observational study | Patients (n=38) with co-occurring schizophrenia and substance use were compared to those with schizophrenia alone (n=32) on illness and socio-demographic variables                                                                                                                                        | Schizophrenia                 |
| Goswami et al, 2004<sup>43</sup> | Cross-sectional observational study | Evaluated reasons for substance use in patients of schizophrenia with dual diagnosis (n=22)                                                                                                                                                                                                                                                     | Schizophrenia                 |
| Aich et al, 2005<sup>44</sup>  | Prospective observational study | Patients (n=38) with co-occurring schizophrenia and substance use were compared to those with schizophrenia alone (n=32) for resolution of symptoms three months after following treatment                                                                                                                                      | Schizophrenia                 |
| Singh et al, 2005<sup>45</sup>  | Cross-sectional observational study | Quality of life measures of dual diagnosis patients with BPAD was compared with BPAD patients and healthy controls and found to be significantly lower                                                                                                                                                                                     | BPAD                          |
| Desai, 2006<sup>46</sup>      | Editorial       | Comment on high rates of comorbidity among psychiatry disorders and discussion on possible explanations                                                                                                                                                                                                                                           | Not applicable                |
| Phillips, 2007<sup>47</sup>   | Cross-sectional observational study | In-depth interviewing of nursing staff caring for dual disorder patients, challenges faced and perceptions                                                                                                                                                                                                                                              | Various disorders             |
| Thirthalli et al, 2008<sup>48</sup> | Letter to editor | Discusses the impact of sociocultural factors on prevalence of substance use disorders in those with psychotic illnesses                                                                                                                                                                                                                                    | Psychosis                     |
psychopathology or a previous history of psychiatric disorders.

Goel and Netto\textsuperscript{14} reported that regular cannabis users presented with hyperactivity, mood changes, delusions and hallucinations. Thacore and Shukla\textsuperscript{15} reported similar presentations. Bagadia \textit{et al.}\textsuperscript{16} explored the causes for vulnerability to psychiatric disorders in daily cannabis users (n=20). Thomas\textsuperscript{23} reported the phenomenology of cannabis use disorders to be vague and of fleeting nature of symptoms. Basu \textit{et al.}\textsuperscript{24} classified the psychological effects of cannabis into three separate syndromes viz. intoxication syndrome, cannabis psychosis syndrome and amotivational syndrome. Basu \textit{et al.}\textsuperscript{25} did a retrospective case control review of 22 patients with cannabis psychosis and 20 control patients of acute psychotic episode to find an association.

Aich \textit{et al.}\textsuperscript{42} reported a prevalence rate of 54.3 per cent. Sixty per cent of them were using cannabis along with tobacco while 42 and 5 per cent were using alcohol and opioids, respectively. On a longitudinal examination of the same sample, it was seen that the substance-using group presented with predominantly positive symptoms (63.2\%) in comparison and also had a faster rate of remission of these symptoms upon treatment. The non-substance-using group showed significantly more negative symptoms\textsuperscript{44}. Similarly, Kulhalli \textit{et al.}\textsuperscript{29} examined 20 inpatient cases of psychosis following cannabis use during a weeklong period of abstinence. On further assessment, seven patients were diagnosed with schizophrenia, 12 were diagnosed with BPAD mania with psychotic symptoms while one had psychotic symptoms not amounting to a diagnosis. The subjects showed increased psychomotor activity, multiple delusions and hallucinations along with unusual thought content. Shrivastava \textit{et al.}\textsuperscript{31} and Grover and Basu\textsuperscript{27} discussed the theories of an association between cannabis use and schizophrenia such as self-medication hypothesis, vulnerability hypothesis,
Studies on various substance use disorders (including cannabis use disorders) and psychiatric disorders: Fourteen studies on dual disorders were included\cite{33,34,37,41,43,45,48,49,52,54,57}. Dubé & Handa\cite{33} showed a five per cent prevalence rate of dual diagnosis in a community survey (n=16,725). Trivedi & Sethi\cite{34} reported 16.4 per cent prevalence of substance misuse in psychiatric outpatients (n=1000). Kumar and Raju\cite{38} reported cannabis abuse in 26.7 per cent individuals with mania. Carey et al\cite{40} reported lower prevalence of cannabis use in people with mental illness in India as compared to other countries. Thirthalli et al\cite{48} also highlighted low prevalence of cannabis dependence in patients of schizophrenia (n=258) in a rural Indian community. Reviews on issues related to the management of dual diagnosis disorders recommended that psychosocial interventions should be implemented along with pharmacotherapy and that the integrated treatment approach is superior\cite{39,52}.

Goswami et al\cite{41} mapped the course of schizophrenia onto the course of substance use in a retrospective study design. Goswami et al\cite{41} contrasted the psychopathology of patients with schizophrenia who used psychoactive substances [alcohol (n=22), cannabis and opioids (n=22)] with patients of schizophrenia who did not use these substances. Alcohol was found to be used more commonly as a self-medicating agent than opioids and cannabis. In general, patients with dual diagnosis reported lesser emotional distress and mitigation of certain symptoms as one of the purposes of using substance.

Singh et al\cite{45} reported the findings on quality of life and associated parameters in patients with dual diagnosis of BPAD and substance dependence. However, the findings of the cannabis users have been presented clubbed together with opioid users and prescription drug users that comprised 37.5 per cent of the study group. Saddichha et al\cite{49} did a comparative analysis of patients with dual diagnosis and ‘pure’ substance use disorders. All patients with schizophrenia and 80 per cent of patients with BPADs were diagnosed with cannabis dependence while 28 per cent of the participants with ‘pure’ substance use disorders had cannabis dependence.

The additive effect of substance use as well the occupational distress faced by female commercial sex workers seeking psychiatric treatment has been studied by Pandiyan et al\cite{57}. Most common substances used were alcohol (100%), tobacco (74%), opioids (14%), cocaine (6%) and cannabis (6%).

Acute psychotic effect of cannabis use and occurrence of common socio-demographic and genetic factors in those affected by cannabis use and psychosis.

Cannabis use disorders and various psychiatric disorders: Five studies\cite{7,13,26,28,32} assessed the comorbid cannabis use disorders and various psychiatric disorders. Grossman\cite{7} described psychiatric symptoms in six individuals who were regular users of cannabis. Dube et al\cite{13}, Sarkar et al\cite{26} and Chaudhury et al\cite{28} reported a rate of 24-52 per cent of cannabis misuse in psychiatric hospital admissions. Sarkar et al\cite{26} found that the common psychiatric comorbidities with cannabis use were other substance use disorders (34%), cannabis psychosis (21%), schizophrenia (14%), mania with psychosis (12%), and unspecified psychosis (7%). Ghosh and Basu\cite{32} reported a high strength of association between cannabis use and psychiatric disorders, chiefly schizophrenia.

Cannabis use disorders and cognitive function: Seven studies\cite{12,17,22} assessed cognitive functioning of cannabis users. Agarwal et al\cite{12} & Wig and Varma\cite{17} reported cognitive disturbances such as poor attention span and memory deficits in bhang users. Mendhiratta et al\cite{18} reported delayed reaction time, poor concentration and poor time estimation in long-term (>10 years) cannabis users. Marked deterioration in cognitive functioning continued to persist in a follow up study\cite{21}. Similar findings were reported by Ray et al\cite{19} in frequent cannabis users.

Conversely, Sethi et al\cite{20} and Varma et al\cite{22} found no significant cognitive deficit, physical health, social functioning or work performance in long-term daily cannabis users. Bannerjee et al\cite{23} compared the cognitive functioning of opioid users, cannabis users and matched controls and reported most deficit in opioid users.

Figure. Time trends of publications on co-occurring cannabis use disorder and psychiatric disorders from India.
Retrospective studies by Aggarwal et al\textsuperscript{53} and Basu et al\textsuperscript{54} on substance-induced psychotic disorders implicated cannabis as one of the chief causative agents for psychosis. Chand et al\textsuperscript{56} noted a 20 per cent prevalence of substance dependence among treatment naive first episode psychosis patients.

Studies on service delivery for individuals with co-occurring cannabis use disorders and psychiatric disorders: In a qualitative study of care providers of dual diagnosis patients Phillips\textsuperscript{47} reported that depressive and anxiety disorders commonly co-occurred in patients with alcohol use, while schizophrenia was usually observed in cannabis-dependent individuals.

Discussion

There is limited published literature on co-occurring cannabis use disorders and psychiatric disorders from India\textsuperscript{50,58,59}. Most studies have used cross-sectional observational design and there are only a few studies that have followed up study subjects prospectively, while some have done a retrospective chart review. The existing literature on co-occurring cannabis use disorders and psychiatric disorders has explored only limited domains. This is despite cannabis being one of the most commonly used substances among those with psychiatric disorder. An update on the progress on exploring the detrimental and sometimes beneficial effects of cannabis use on various psychiatric disorders suggests that we still have a long road of exploration ahead of us\textsuperscript{60}.

Most of the studies on comorbid cannabis use disorders and psychiatric disorders have focussed on psychoses. Reviews on the subject uphold the phenomenology described in the reviewed literature following long-term and short-term cannabis use\textsuperscript{61}. The information gathered indicates an association of psychiatric comorbidity and cognitive decline in individuals with cannabis use disorders. A collective analysis on the data generated on behavioural changes associated with cannabis use suggests similar findings\textsuperscript{62}. Studies in recent years among patients with co-occurring schizophrenia and substance use disorders have supported the ‘vulnerability hypothesis model’ to explain the association between cannabis use and schizophrenia. Research reiterates that cannabis use could interact with pre-existing genetic and environmental factors to lead to symptoms of schizophrenia\textsuperscript{63}. It is to be mentioned here that antipsychotic potential of cannabidiol is being explored while support for vulnerability of cannabis users to develop psychosis gathers ground\textsuperscript{64}.

Cognitive effect of cannabis is a commonly explored area in Indian studies. The studies have commonly chosen chronic users of cannabis and compared the deficits between weaker and stronger preparation users to substantiate their findings. The reports suggested a decline in performance among those with long-term cannabis use. The predominant cognitive deficit observed in these studies was poor attention and concentration along with memory impairment. The preponderance of developing cognitive defects and psychotic disturbances in younger and more frequent users of cannabis is a finding of recent research as well\textsuperscript{65}.

Overall, the literature review points towards a high frequency of psychiatric symptoms in those with substance use disorders with a specific preponderance of cannabis-associated comorbidity of both psychotic and affective disorders with a higher strength of association with psychotic syndromes. A systematic review of worldwide literature echoes these findings\textsuperscript{66}. Another longitudinal study on patients with mood disorders found a lack of association between course of the illness and cannabis use\textsuperscript{67}.

In conclusion, several Indian studies have described the adverse effects of cannabis use, and the review of research suggests a high prevalence of psychiatric disorders among those with cannabis use disorders. The psychiatric comorbidity usually found in cannabis users was schizophrenia and other psychotic disorders. Research suggests that cannabis use alters the age of onset, course and presentation of psychotic illness in vulnerable individuals. Further high-quality research on cannabis use-associated psychosis is desired to understand impact of one on the other. Findings suggest that cannabis use has an association with other mental disorders indicating a modest strength of association with mood and anxiety spectrum disorders. Cognitive deficits are frequently reported among chronic and heavy cannabis users. Exploration of neurobiological aspects of dual disorders of cannabis use and psychiatric disorders has been inconclusive and Indian literature on this aspect is scarce.

Conflicts of Interest: None.

References

1. United Nations Office on Drugs and Crime. World Drug Report 2014. New York: United Nations Publication; 2014.
2. Ray R, editor. The Extent, Pattern and Trends of Drug Abuse in India - National Survey: New Delhi. Ministry of Social Justice and Empowerment, Government of India and United Nations Office on Drugs and Crime; 2004.

3. Leweke FM, Koethe D. Cannabis and psychiatric disorders: It is not only addiction. Addict Biol 2008; 13: 264-75.

4. Johns A. Psychiatric effects of cannabis. Br J Psychiatry 2001; 178: 116-22.

5. Hall W, Degenhardt L. Cannabis use and the risk of developing a psychotic disorder. World Psychiatry 2008; 7: 68-71.

6. Dhumiboy J. A brief resume of the types of insanity commonly met with in India with a full description of “Indian hemp insanity” peculiar to the country. J Ment Sci 1930; 75: 254.

7. Grossman W. Adverse reactions associated with Cannabis products in India. Ann Intern Med 1969; 70: 529-33.

8. Chopra GS. Marijuana and adverse psychotic reactions. Evaluation of different factors involved. Bull Nanc 1971; 23: 15-22.

9. Varma L. Cannabis psychosis. Indian J Psychiatry 1972; 14: 241.

10. Thacore VR. Bhang psychosis. Br J Psychiatry 1973; 123: 225-9.

11. Chopra GS, Smith JW. Psychotic reactions following cannabis use in East Indians. Arch Gen Psychiatry 1974; 30: 24-7.

12. Agarwal A, Sethi B, Gupta S. Physical and cognitive effects of chronic Bhang (Cannabis) intake. Indian J Psychiatry 1975; 17: 1.

13. Dube KC, Jain SC, Basu AK, Kumar N. Patterns of the drug habit in hospitalized psychiatric patients. Bull Nanc 1975; 27: 1-10.

14. Goel D, Netto D. Cannabis: The habit and psychosis. Indian J Psychiatry 1975; 17: 238-43.

15. Thacore VR, Shukla SR. Cannabis psychosis and paranoid schizophrenia. Arch Gen Psychiatry 1976; 33: 383-6.

16. Bagadia V, Copalani J, Pradhan P, Shah L. Habitual use of Cannabis indica in psychiatric patients. Indian J Psychiatry 1976; 18: 141-6.

17. Wig NN, Varma VK. Patterns of long-term heavy cannabis use in north India and its effects on cognitive functions: A preliminary report. Drug Alcohol Depend 1977; 2: 211-9.

18. Menhiratta SS, Wig NN, Verma SK. Some psychological correlates of long-term heavy cannabis users. Br J Psychiatry 1978; 132: 482-6.

19. Ray R, Prabhu GG, Mohan D, Nath LM, Neki JS. The association between chronic cannabis use and cognitive functions. Drug Alcohol Depend 1978; 3: 365-8.

20. Sethi BB, Trivedi JK, Singh H. Long term effects of cannabis. Indian J Psychiatry 1981; 23: 224-9.

21. Mendhiratta SS, Varma VK, Dang R, Malhotra AK, Das K, Nehra R. Cannabis and cognitive functions: A re-evaluation study. Br J Addict 1988; 83: 749-53.

22. Varma VK, Malhotra AK, Dang R, Das K, Nehra R. Cannabis and cognitive functions: A prospective study. Drug Alcohol Depend 1988; 21: 147-52.

23. Thomas H. Psychiatric symptoms in cannabis users. Br J Psychiatry 1993; 163: 141-9.

24. Basu D, Malhotra A, Varma VK. Cannabis related psychiatric syndromes: A selective review. Indian J Psychiatry 1994; 36: 121-8.

25. Basu D, Malhotra A, Bhagat A, Varma VK. Cannabis psychosis and acute schizophrenia. A case-control study from India. Eur Addict Res 1999; 5: 71-3.

26. Sarkar J, Murthy P, Singh SP. Psychiatric morbidity of cannabis abuse. Indian J Psychiatry 2003; 45: 182-8.

27. Grover S, Basu D. Cannabis and psychopathology: Update 2004. Indian J Psychiatry 2004; 46: 299-309.

28. Chaudhury S, Sudarsanan S, Saluja SK, Srivastava K. Cannabis use in psychiatric patients. Med J Armed Forces India 2005; 61: 117-20.

29. Kulhalli V, Isaac M, Murthy P. Cannabis-related psychosis: Presentation and effect of abstinence. Indian J Psychiatry 2007; 49: 256-61.

30. Parakh P, Basu D. Cannabis and psychosis: Have we found the missing links? Asian J Psychiatry 2013; 6: 281-7.

31. Shrivastava A, Johnston M, Terpstra K, Bureau Y. Cannabis and psychosis: Neurobiology. Indian J Psychiatry 2014; 56: 8-16.

32. Ghosh A, Basu D. Cannabis and psychopathology: The meandering journey of the last decade. Indian J Psychiatry 2015; 57: 140-9.

33. Dubé KC, Handa SK. Drug use in health and mental illness in an Indian population. Br J Psychiatry 1971; 118: 345-6.

34. Trivedi J, Sethi B. Drug abuse in psychiatric patients. Indian J Psychiatry 1978; 21: 345-8.

35. Thomas MG, Mohan D, Sahasi G, Prabhu GG. Personality and attitude correlates of drug abuse amongst students of a high school in Delhi: A replicated study. Indian J Med Res 1979; 69: 990-5.

36. Kisore P, Lal N, Trivedi JK, Dalal PK, Agra VM. A study of comorbidity in psychoactive substance dependence patients. Indian J Psychiatry 1994; 36: 133-7.

37. Bannerejee S, Mukhopadhyay A, Shukla V. Cognitive deterioration of male drug addicts. J Indian Acad Appl Psychol 1997; 23: 13-8.

38. Kumar PN, Raju SS. Impact of substance abuse comorbidity on psychopathology and pattern of remission in mania. Indian J Psychiatry 1998; 40: 357-63.

39. Basu D, Gupta N. Management of “dual diagnosis” patients: Consensus, controversies and considerations. Indian J Psychiatry 2000; 42: 34-47.

40. Carey KB, Carey MP, Chandra PS. Psychometric evaluation of the alcohol use disorders identification test and short drug abuse screening test with psychiatric patients in India. J Clin Psychiatry 2003; 64: 767-74.
41. Goswami S, Singh G, Mattoo SK, Basu D. Courses of substance use and schizophrenia in the dual-diagnosis patients: Is there a relationship? Indian J Med Sci 2003; 57 : 338-46.
42. Aich TK, Sinha VK, Khess CR, Singh S. Demographic and clinical correlates of substance abuse comorbidity in schizophrenia. Indian J Psychiatry 2004; 46 : 135-9.
43. Goswami S, Mattoo SK, Basu D, Singh G. Substance-abusing schizophrenics: Do they self-medicate? Am J Addict 2004; 13 : 139-50.
44. Aich T, Sinha V, Khess C, Singh S. Substance abuse co-morbidity in schizophrenia: An inpatient study of course and outcome. Indian J Psychiatry 2005; 47 : 33-8.
45. Singh J, Mattoo SK, Sharan P, Basu D. Quality of life and its correlates in patients with dual diagnosis of bipolar affective disorder and substance dependence. Bipolar Disord 2005; 7 : 187-91.
46. Desai NG. Comorbidity in psychiatry: Way forward or a conundrum? Indian J Psychiatry 2006; 48 : 75-7.
47. Phillips PA. Dual diagnosis: An exploratory qualitative study of staff perceptions of substance misuse among the mentally ill in Northern India. Issues Ment Health Nurs 2007; 28 : 1309-22.
48. Thirthalli J, Venkatesh BK, Gangadhar BN. Psychoses and illicit drug use: Need for cross-cultural studies. Acta Psychiatr Scand 2008; 118 : 86.
49. Saddichha S, Sur S, Sinha BN, Khess CR. How is substance use linked to psychosis? A study of the course and patterns of substance dependence in psychosis. Subst Abus 2010; 31 : 58-67.
50. Srivastava A, Sreejayan K, Joseph AM, Sharma PS. Indian research on comorbidities. Indian J Psychiatry 2010; 52 (Suppl 1) : S246-9.
51. Lavania S, Ram D, Praharaj SK, Khan AH, Pattoojshi A. Deliberate self-harm in nondepressed substance-dependent patients. J Addict Med 2012; 6 : 247-52.
52. Murthy P, Chand P. Treatment of dual diagnosis disorders. Curr Opin Psychiatry 2012; 25 : 194-200.
53. Aggarwal M, Banerjee A, Singh SM, Mattoo SK, Basu D. Substance-induced psychotic disorders: 13-year data from a de-addiction centre and their clinical implications. Asian J Psychiatry 2012; 5 : 220-4.
54. Basu D, Sarkar S, Mattoo S. Psychiatric comorbidity in patients with substance use disorders attending an addiction treatment center in India over 11 years: Case for a specialized ‘dual diagnosis clinic’. J Dual Diagn 2013; 9 : 23-9.
55. Gupta M, Kumar K, Garg PD. Dual diagnosis vs triple diagnosis in HIV: A comparative study to evaluate the differences in psychopathology and suicidal risk in HIV positive male subjects. Asian J Psychiatry 2013; 6 : 515-20.
56. Chand P, Thirthalli J, Murthy P. Substance use disorders among treatment naive first-episode psychosis patients. Compr Psychiatry 2014; 55 : 165-9.
57. Pandiyan K, Chandrasekhar H, Madhusudhan S. Psychological morbidity among female commercial sex workers with alcohol and drug abuse. Indian J Psychiatry 2012; 54 : 349-51.
58. Murthy P, Manjunatha N, Subodh BN, Chand PK, Benegal V. Substance use and addiction research in India. Indian J Psychiatry 2010; 52 (Suppl 1) : S189-99.
59. Kumar V, Kumar P, Bhatia M, Jhanjee A. Substance abuse and comorbidity. Delhi Psychiatry J 2010; 13 : 36-42.
60. Haney M, Evins AE. Does cannabis cause, exacerbate or ameliorate psychiatric disorders? An oversimplified debate discussed. Neuropsychopharmacology 2016; 41 : 393-401.
61. Wilkinson ST, Radhakrishnan R, D’Souza DC. Impact of cannabis use on the development of psychotic disorders. Curr Addict Rep 2014; 1 : 115-28.
62. Repp K, Raich A. Marijuana and Health: A Comprehensive Review of 20 Years of Research. Washington: Department of Health and Human Services; 2014.
63. Green IW, Glausier JR. Different paths to core pathology: The equifinal model of the Schizophrenia syndrome. Schizophr Bull 2016; 42 : 542-9.
64. Manseau MW, Goff DC. Cannabinoids and schizophrenia: Risks and therapeutic potential. Neurotherapeutics 2015; 12 : 816-24.
65. Albertella L, Le Pelley ME, Copeland J. Cannabis use, schizotypy, and negative priming. Psychiatry Res 2015; 228 : 404-10.
66. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet 2007; 370 : 319-28.
67. Feingold D, Weiser M, Rehm J, Lev-Ran S. The association between cannabis use and mood disorders: A longitudinal study. J Affect Disord 2015; 172 : 211-8.

Reprint requests: Dr Yatan Pal Singh Balhara, Department of Psychiatry, National Drug Dependence Treatment Centre, WHO Collaborating Centre on Substance Abuse, All India Institute of Medical Sciences, New Delhi 110 029, India e-mail: ypsbalhara@gmail.com